Study of Tumor-Infiltrating T Cells in Advanced Stage III or IV Ovarian Epithelial Cancer After Surgery

What this Trial Is About

Researchers are studying tumor tissue samples from patients who had surgery for advanced stage III or stage IV ovarian epithelial cancer. The study aims to see if tumor-infiltrating T lymphocytes TILs can help predict how long patients live without their cancer getting worse and their overall survival. This research may improve understanding of how the immune system affects treatment outcomes in ovarian cancer. The study uses previously collected tumor tissue samples from patients who had either optimal or suboptimal cytoreductive surgery. These samples are analyzed in the laboratory using immunohistochemistry and double immunofluorescence assays to detect TILs. Patients are grouped based on the extent of their surgery results to validate the predictive value of TILs for progression-free and overall survival. Participants have already undergone surgery and chemotherapy as part of other clinical trials, and their tissue samples and clinical data are used for analysis. Researchers review demographic, follow-up, and disease measurements to evaluate the role of TILs. The main outcomes studied are survival curves showing progression-free survival and overall survival. This observational study involves no new treatments or interventions for participants.

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer